Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial

导出原文传递

翻译打印收藏纠错

作者： Yamamoto, D. ^[1] ; Iwase, S. ^[2] ; Tsubota, Y. ^[3] ; Ariyoshi, K. ^[4] ; Kawaguchi, T. ^[5] ; Miyaji, T. ^[6] ; Sueoka, N. ^[7] ; Yamamoto, C. ^[8] ; Teramoto, S. ^[9] ; Odagiri, H. ^[10] ; Kitamura, K. ; Nagumo, Y. ; Yamaguchi, T.

作者单位： Nagumo Clin, Breast Unit, Tokyo, Japan ^[1] Hirosaki Natl Hosp, Dept Surg, Hirosaki, Aomori, Japan ^[2] Nagumo Clin, Breast Unit, Fukuoka, Japan ^[3] Kyushu Cent Hosp, Dept Breast Surg, Fukuoka, Japan ^[4] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Pract Pharm, Tokyo, Japan ^[5] Univ Tokyo, Inst Med Sci, Dept Palliat Med, Tokyo 1138655, Japan ^[6] Univ Tokyo, Grad Sch Med, Dept Clin Trial Data Management, Bunkyo Ku, Tokyo 1138655, Japan ^[7] Seiko Hosp, Dept Internal Med, Neyagawa, Osaka, Japan ^[8] Kansai Med Univ, Dept Surg, Osaka, Japan ^[9] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Miyagi 980, Japan ^[10]

关键词 S-1 Capecitabine Metastatic breast cancer Recurrent breast cancer Clinical trial

发布时间 2015-09-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交